Optimizing ACS Management: Quality Metrics, Enhanced Digitization & Patient Outcome Feedback in PMcardio’s Latest Update
Our new major update includes a dashboard and insights, real-time outcome feedback, enhanced digitization, and faster explainability. With AI-powered ECG interpretation and advanced analytics, healthcare institutions gain actionable data to optimize clinical workflows, improve patient outcomes, and drive efficiency.
We’re excited to announce a significant update to PMcardio for Organizations, bringing two new features and two key enhancements designed to improve your clinical workflows.
1. Dashboard: Quality Metrics & Insight
We’re introducing comprehensive statistical dashboards that consolidate all ACS pathway-related data into one easy-to-access platform. This feature:
- Reduces administrative burden by centralizing all relevant patient path metrics.
- Enables cost savings by automating data collection and reducing manual effort.
- Improves patient care through trend analysis, identifying gaps, and optimizing workflows.
- Enhances regulatory compliance by simplifying reporting and making data more accessible.
Available to all users but specifically designed for hospital management, patient pathway coordinators, and system administrators, this dashboard consolidates key performance indicators, such as the total number of STEMI cases, E2B Times (ECG upload-to-balloon time), and many more, into a single platform, reducing fragmentation and improving efficiency.
2. Patient Outcomes Feedback Loop
We’re closing the loop on ACS care coordination with a patient outcomes feedback feature, which enables:
- Standardized feedback collection for hospitals to track their diagnostic accuracy and effectiveness.
- Objective outcome gathering to assess real-world performance.
- Enhanced learning for healthcare professionals, ensuring they receive insights on past cases.
3. Digitization v3.1 Upgrade
We are upgrading our Digitization model to version 3.1, bringing improved accuracy and better performance based on extensive testing. This update ensures:
- More precise lead detection, with improved robustness against noise, such as horizontal lines and paper edges.
- Higher accuracy in ECG digitization, ensuring better column separation and reducing errors for more reliable diagnostics.
- Enhanced detection of low-quality images, minimizing the risk of misinterpretation due to poor image quality.
4. Lightning-Speed Explainability
Our AI Explainability feature is now significantly faster, enhancing efficiency in ECG report generation. Understanding the importance of rapid insights, we have optimized the process, making it five times faster – ensuring a seamless experience without unnecessary delays.
Experience the New PMcardio Today
These enhancements make PMcardio an even more powerful tool for cardiovascular care. Update your PMcardio App on your phone today and start leveraging these features straight away!
Optimize STEMI patient pathway with certified AI
The impact of PMcardio at the Cardiovascular Centre Aalst, Belgium:
- 68% reduction in false positive STEMI alerts
- 100% sensitivity in true positive STEMI patients
- 34% reduction in ECG to balloon time for STEMI patients
- 50% decrease in door-to-ECG time month-over-month
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.